trending Market Intelligence /marketintelligence/en/news-insights/trending/9VqvojFXTV8D7tyeZKg_Ow2 content esgSubNav
In This List

Novartis' Cosentyx reduces symptoms of arthritis subtype in late-stage study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novartis' Cosentyx reduces symptoms of arthritis subtype in late-stage study

Novartis AG said Cosentyx helped reduce the symptoms of a certain form of arthritis that affects the spine and pelvis, meeting the main goal of a late-stage study.

The ongoing phase 3 trial, dubbed Prevent, is evaluating the safety and effectiveness of Cosentyx in treating 555 patients with non-radiographic axial spondyloarthritis, or nr-AxSpA, a condition of abnormal immune response that causes inflammation in the spine and pelvis. In nr-AxSpA, the disease causes symptoms, but joint damage is not visible on X-ray.

After 52 weeks of treatment, patients treated with Cosentyx demonstrated a significant and clinically meaningful reduction in disease activity. The drug's safety profile was consistent with other previous studies, and no new safety signals were identified, Novartis noted.

The Swiss drugmaker plans to present detailed data from Prevent at a future scientific congress.

Cosentyx is already approved for psoriatic arthritis, plaque psoriasis and ankylosing spondylitis in more than 70 countries.